| Followers | 83 |
| Posts | 36201 |
| Boards Moderated | 0 |
| Alias Born | 03/09/2010 |
Friday, February 04, 2011 10:42:49 AM
My suggestion is to take some profits along the way. If the company has success with the clinical trial, and is not just some phony baloney PR success, then we could see this rise a bit. Upon CE mark approval it could rise a bit more. I think it is possible that the pps could get back to .40 or so where a lot of the current bagholders bought in. I would get out at that point because when the sales numbers come in, this will disappoint. I see some trading opportunities in all of this, but then the stock settles back and stagnates for a long while.
Recent CTSO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 11:00:20 AM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/30/2026 11:04:46 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:27:51 PM
- CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights • PR Newswire (US) • 03/25/2026 08:05:00 PM
- CytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026 • PR Newswire (US) • 03/19/2026 01:44:00 PM
- CytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights • PR Newswire (US) • 03/05/2026 12:00:00 PM
- CytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update • PR Newswire (US) • 01/12/2026 12:00:00 PM
- CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025 • PR Newswire (US) • 12/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2025 02:09:45 AM
- Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London • PR Newswire (US) • 11/17/2025 10:42:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2025 09:34:39 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 09:32:19 PM
- CytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update • PR Newswire (US) • 11/13/2025 09:05:00 PM
- CytoSorbents to Participate at the Jefferies Global Healthcare Conference in London • PR Newswire (US) • 11/11/2025 12:00:00 PM
- CytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights • PR Newswire (US) • 10/30/2025 11:00:00 AM
- In Memoriam: Dr. Robert Hawes Bartlett (1939-2025) - Father of Extracorporeal Membrane Oxygenation (ECMO) and Former CytoSorbents Chief Medical Officer • PR Newswire (US) • 10/28/2025 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/03/2025 08:20:54 PM
- CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in Copenhagen • PR Newswire (US) • 09/29/2025 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2025 08:35:38 PM
- CytoSorbents Provides DrugSorb-ATR Regulatory Update • PR Newswire (US) • 09/16/2025 11:00:00 AM
- CytoSorbents To Host Global Webinar on "Turning the Tide in Sepsis and Septic Shock: Real World Insights with CytoSorb" in Recognition of World Sepsis Day • PR Newswire (US) • 09/08/2025 11:00:00 AM
- CytoSorbents to Present at the H.C. Wainwright 27th Annual Global Investment Conference • PR Newswire (US) • 09/05/2025 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2025 08:05:59 PM
- CytoSorbents Updates U.S. FDA Regulatory Status of DrugSorb-ATR • PR Newswire (US) • 08/20/2025 11:00:00 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/19/2025 07:47:54 PM
